Partnering Door Opens For Sarepta With 48-Week Data In Hand
This article was originally published in The Pink Sheet Daily
Executive Summary
Sarepta Therapeutics’ positive data on its lead muscular dystrophy drug eteplirsen puts the company in a strong position at the partnering table and sets the stage for a neck and neck race with GSK/Prosensa to bring the first treatment for the rare disease to market.